BMC Cancer

Table 3 Prognostic factors of patients 70 years and older

From: The efficacy of adjuvant chemotherapy for older adults with stage II/III gastric cancer: a retrospective cohort study

	Univariate analysis				Multivariate analysis
	HR	(95% CI)	P-value		HR	(95% CI)	P-value
Adjuvant chemotherapy
No	1.00				1.00
Yes	0.42	(0.24–0.73)	0.002		0.37	(0.20–0.68)	0.002
Sex
Male	1.00				1.00
Female	0.50	(0.26–0.98)	0.042		0.58	(0.29–1.16)	0.126
BMI
18.5–23.9	1.00
< 18.5	0.89	(0.27–2.95)	0.854
≥ 24.0	0.81	(0.45–1.43)	0.457
ECOG performance status
0–1	1.00				1.00
2–4	2.39	(1.35–4.24)	0.003		1.79	(0.95–3.36)	0.070
aCCI
0–3	1.00
≥ 4	1.93	(0.91–4.11)	0.088
Year of diagnosis
2009–2013	1.00
2014–2019	1.51	(0.86–2.63)	0.149
Histologic grade
Grade I/II	1.00
Grade III	0.98	(0.48–2.02)	0.965
Signet-ring feature
No	1.00
Yes	0.81	(0.41–1.61)	0.545
Gastrectomy type
Subtotal gastrectomy	1.00				1.00
Total gastrectomy	1.92	(1.11–3.31)	0.019		1.17	(0.65–2.10)	0.600
Lymphadenectomy type
< D2 dissection	1.00				1.00
D2 dissection	0.53	(0.31–0.92)	0.025		0.74	(0.41–1.33)	0.309
Stage
Stage II	1.00				1.00
Stage III	3.16	(1.68–5.93)	< 0.001		3.96	(2.03–7.73)	< 0.001
Lymphovascular invasion
No	1.00
Yes	0.88	(0.48–1.62)	0.677
Perineural invasion
No	1.00
Yes	1.72	(0.98–3.03)	0.060
CEA level ≥ 5 U/mL
No	1.00
Yes	1.86	(0.96–3.61)	0.064
CA 19 − 9 level ≥ 34 U/mL
No	1.00
Yes	1.44	(0.69–3.04)	0.332
NLR
≤ 2.6	1.00
> 2.6	1.49	(0.84–2.64)	0.176
PLR
≤ 166	1.00
> 166	1.60	(0.91–2.80)	0.103

aCCI, age-adjusted Charlson comorbidity index; BMI, body mass index; CA 19 − 9, carbohydrate antigen 19 − 9; CEA, carcinoembryonic antigen; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com